{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T20:35:21Z","timestamp":1794602121828,"version":"4.9.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Jiangsu Hengrui Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1038\/s41591-025-03781-w","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T09:02:22Z","timestamp":1752656542000},"page":"3037-3046","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["The antibody\u2013drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial"],"prefix":"10.1038","volume":"31","author":[{"given":"Dan-Yun","family":"Ruan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Xiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Xia","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Wen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Jun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuo-Xing","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan-Yu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Xia","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Qiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-Ya","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Ying","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Rong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Gang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Tao","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He-Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-Sheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Li","family":"Suo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Nuo","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Dong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Chen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Ai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4774-6235","authenticated-orcid":false,"given":"Miao-Zhen","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9771-8534","authenticated-orcid":false,"given":"Rui-Hua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"3781_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"3781_CR2","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/cac2.12627","volume":"45","author":"X Diao","year":"2025","unstructured":"Diao, X. et al. Cancer situation in China: an analysis based on the global epidemiological data released in 2024. Cancer Commun. (Lond.) 45, 178\u2013197 (2025).","journal-title":"Cancer Commun. (Lond.)"},{"key":"3781_CR3","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick, F. et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33, 1005\u20131020 (2022).","journal-title":"Ann. Oncol."},{"key":"3781_CR4","unstructured":"NCCN Clinical Practice Guidelines. Gastric Cancer 2025 (version 2.2025\u2013April 4, 2025); https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/gastric.pdf"},{"key":"3781_CR5","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S1470-2045(19)30088-9","volume":"20","author":"K Shitara","year":"2019","unstructured":"Shitara, K. et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. Lancet Oncol. 20, 827\u2013836 (2019).","journal-title":"Lancet Oncol."},{"key":"3781_CR6","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara, K. et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N. Engl. J. Med. 382, 2419\u20132430 (2020).","journal-title":"N. Engl. J. Med."},{"key":"3781_CR7","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s10120-014-0402-y","volume":"18","author":"E Van Cutsem","year":"2015","unstructured":"Van Cutsem, E. et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 18, 476\u2013484 (2015).","journal-title":"Gastric Cancer"},{"key":"3781_CR8","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41571-024-00874-2","volume":"21","author":"I Nakayama","year":"2024","unstructured":"Nakayama, I. et al. Claudin 18.2 as a novel therapeutic target. Nat. Rev. Clin. Oncol. 21, 354\u2013369 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"3781_CR9","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","volume":"14","author":"U Sahin","year":"2008","unstructured":"Sahin, U. et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin. Cancer Res. 14, 7624\u20137634 (2008).","journal-title":"Clin. Cancer Res."},{"key":"3781_CR10","doi-asserted-by":"publisher","first-page":"7380","DOI":"10.1128\/MCB.21.21.7380-7390.2001","volume":"21","author":"T Niimi","year":"2001","unstructured":"Niimi, T. et al. claudin-18, a novel downstream target gene for the T\/EBP\/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing. Mol. Cell. Biol. 21, 7380\u20137390 (2001).","journal-title":"Mol. Cell. Biol."},{"key":"3781_CR11","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1093\/jjco\/hyz068","volume":"49","author":"C Rohde","year":"2019","unstructured":"Rohde, C. et al. Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma. Jpn. J. Clin. Oncol. 49, 870\u2013876 (2019).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"3781_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-44874-0","volume":"9","author":"G Zhu","year":"2019","unstructured":"Zhu, G. et al. Targeting CLDN18.2 by CD3 bispecific and ADC modalities for the treatments of gastric and pancreatic cancer. Sci. Rep. 9, 8420 (2019).","journal-title":"Sci. Rep."},{"key":"3781_CR13","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3390\/jpm11111095","volume":"11","author":"A Pellino","year":"2021","unstructured":"Pellino, A. et al. Association of CLDN18 protein expression with clinicopathological features and prognosis in advanced gastric and gastroesophageal junction adenocarcinomas. J. Pers. Med 11, 1095 (2021).","journal-title":"J. Pers. Med"},{"key":"3781_CR14","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.21037\/jgo-20-344","volume":"11","author":"B Xu","year":"2020","unstructured":"Xu, B. et al. Highly expressed Claudin18.2 as a potential therapeutic target in advanced gastric signet-ring cell carcinoma (SRCC). J. Gastrointest. Oncol. 11, 1431\u20131439 (2020).","journal-title":"J. Gastrointest. Oncol."},{"key":"3781_CR15","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.21037\/jgo-22-462","volume":"13","author":"W Weng","year":"2022","unstructured":"Weng, W. et al. Decreased expression of claudin-18.2 in alpha-fetoprotein-producing gastric cancer compared to conventional gastric cancer. J. Gastrointest. Oncol. 13, 1035\u20131045 (2022).","journal-title":"J. Gastrointest. Oncol."},{"key":"3781_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101710","volume":"5","author":"G Xu","year":"2024","unstructured":"Xu, G. et al. CMG901, a Claudin18.2-specific antibody-drug conjugate, for the treatment of solid tumors. Cell Rep. Med. 5, 101710 (2024).","journal-title":"Cell Rep. Med."},{"key":"3781_CR17","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00543","volume":"8","author":"R Waters","year":"2024","unstructured":"Waters, R. et al. Retrospective study of claudin 18 isoform 2 prevalence and prognostic association in gastric and gastroesophageal junction adenocarcinoma. JCO Precis. Oncol. 8, e2300543 (2024).","journal-title":"JCO Precis. Oncol."},{"key":"3781_CR18","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1007\/s10120-024-01518-1","volume":"27","author":"K Shitara","year":"2024","unstructured":"Shitara, K. et al. Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Gastric Cancer 27, 1058\u20131068 (2024).","journal-title":"Gastric Cancer"},{"key":"3781_CR19","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah, M. A. et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat. Med. 29, 2133\u20132141 (2023).","journal-title":"Nat. Med."},{"key":"3781_CR20","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1056\/NEJMc2409512","volume":"391","author":"K Shitara","year":"2024","unstructured":"Shitara, K. et al. Zolbetuximab in gastric or gastroesophageal junction adenocarcinoma. N. Engl. J. Med. 391, 1159\u20131162 (2024).","journal-title":"N. Engl. J. Med."},{"key":"3781_CR21","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S1470-2045(24)00636-3","volume":"26","author":"DY Ruan","year":"2025","unstructured":"Ruan, D. Y. et al. Claudin 18.2-targeting antibody\u2013drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial. Lancet Oncol. 26, 227\u2013238 (2025).","journal-title":"Lancet Oncol."},{"key":"3781_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejca.2018.05.007","volume":"100","author":"U Sahin","year":"2018","unstructured":"Sahin, U. et al. A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer. Eur. J. Cancer 100, 17\u201326 (2018).","journal-title":"Eur. J. Cancer"},{"key":"3781_CR23","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1093\/annonc\/mdz199","volume":"30","author":"O T\u00fcreci","year":"2019","unstructured":"T\u00fcreci, O. et al. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann. Oncol. 30, 1487\u20131495 (2019).","journal-title":"Ann. Oncol."},{"key":"3781_CR24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1517\/14740338.4.1.45","volume":"4","author":"K Seiter","year":"2005","unstructured":"Seiter, K. Toxicity of the topoisomerase I inhibitors. Expert Opin. Drug Saf. 4, 45\u201353 (2005).","journal-title":"Expert Opin. Drug Saf."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03781-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03781-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03781-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:10:10Z","timestamp":1788516610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03781-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["3781"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03781-w","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"assertion":[{"value":"22 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.-H.X. has served in a consulting or advisory role for Bristol Myers Squibb, Merck Serono, Roche, Astellas, AstraZeneca, Junshi, Hengrui, BeiGene and CPPC. S.-C.W., A.-A.Y. and J.X. are employed by Jiangsu Hengrui Pharmaceuticals Co., Ltd. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}